FindTrial
Sign In

Clinical study of Tiktadi Ghrita Ointment on stretchmarks in pregnant women

Pharmaceutico-analytical study and clinical evaluation of Tiktadi Ghrita Ointment in Kikkisa with special reference to Striae gravidarum: A Randomized Controlled Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/078715
Enrollment
64
Registered
2024-12-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O268- Other specified pregnancy relatedconditions

Interventions

None listed

Sponsors

Dr Alka Gajanan Khade
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients willingly participating in the trial and giving consent form. • Selection of patient will be Primigravida only. • Women diagnosed with symptoms of Kikkisa – 1. Vaivarnya (Discoloration) 2. Kandu (Itching) 3. Vidah(Burning sensation) 4. Rekha Swarupa Twak Sankocha (Linear line marking and contractions of the skin in the abdomen).

Exclusion criteria

Exclusion criteria: 1.Women suffering from any other skin diseases except Kikkisa. 2.Known case of any systemic illness like tuberculosis,HIV, Hepatitis B, Hepatitis C, Diabetes mellitus, Hyperbilirubinemia,etc 3.Presence of any surgical scar on the abdomen. 4.High-risk pregnancy. (multiple pregnancy, pregnancy induced hypertension, Polyhydramnios, etc.)

Design outcomes

Primary

MeasureTime frame
Pharmaceutico-analytical Studies of Tiktadi Ghrita OintmentTimepoint: 6 Months—

Secondary

MeasureTime frame
This study may prove Tiktadi Ghrita Ointment as effective treatment in the management of KikkisaTimepoint: Follow up on 15th,30th & 45th Day—

Countries

India

Contacts

Public ContactDr Raman Belge

Shri Ayurveda Mahavidyalaya, Nagpur

ramanbelge@gmail.com9822879010

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026